Neoplasie della mammella

Neoplasie della mammella

The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human B lymphocytes

J Biol Chem. 1995 Mar 31;270(13):7037-40.
Steinhilber D, Brungs M, Werz O, Wiesenberg I, Danielsson C, Kahlen JP, Nayeri S, Schräder M, Carlberg C.
5-lipoxygenase is the natural RZR alpha responding gene.New perspective in the involvement of MLT in inflammatory and immunological reactions.
Retinoid Z receptor (RZR alpha and beta)

Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone

Br J Cancer. 1995 Apr;71(4):854-6.
Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G.
Concomitant administration of MLT (os,20mg/day) may induce tumour regressions in metastatic breast cancer patients refractory to TMX alone.
Melatonin (MLT) Tamoxifen (TMX)

Serial transplants of DMBA-induced mammary tumors in Fischer rats as model system for human breast cancer. IV. Parallel changes of biopterin and melatonin indicate interactions between the pineal gland and cellular immunity in malignancy

Oncology. 1995 Jul-Aug;52(4):278-83.
Bartsch C, Bartsch H, Buchberger A, Rokos H, Mecke D, Lippert TH.
Clear stimulation of the immune system and Mlt at early but inhibition at advanced stages of cancer.
Mlt and cellular immunity

A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients

Oncol Rep. 1995 Sep;2(5):871-3.
Lissoni P, Ardizzoia A, Barni S, Paolorossi F, Tancini G, Meregalli S, Esposti D, Zubelewicz B, Braczowski R.
Association of MLT(20 mg/day orally) may make TMX effective also in ER-negative metastatic breast cancer patients.
Tamoxifen (TMX) Melatonin(MLT) Estrogen receptor (ER)

Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasms

Oncol Rep. 1995 Nov;2(6):1063-8.
Lissoni P, Ardizzoia A, Barni S, Brivio F, Tisi E, Rovelli F, Tancini G, Maestroni G, Fumagalli L.
Induce objective tumor regressions in most advanced solid tumor histotypes by low-dose IL-2 plus MLT (orally at 40 mg/day).
Interleukin-2 (IL.2)


Abbonamento a RSS - Neoplasie della mammella